Results 21 to 30 of about 5,730 (206)

Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications [PDF]

, 2015
One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and ...
Gandhi, Mona A., Kaur, Kirpal, Slish, Judianne   +2 more
core   +2 more sources

Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms

Molecules, 2020
A simple, rapid, sensitive, and precise reversed-phase liquid chromatographic method was developed and validated for the simultaneous determination of four direct-acting antivirals, sofosbuvir (SF), ledipasvir (LD), declatasvir (DC), and simeprevir (SM),
Essam Ezzeldin, Nisreen F. Abo-Talib, Marwa H. Tammam, Yousif A. Asiri, Abd El-Galil E. Amr, Abdulrahman A. Almehizia   +5 more
doaj   +1 more source

A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients. [PDF]

, 2015
INTRODUCTION:This study compares the expected occurrence of contraindicated drug-drug interactions (XDDIs) when simeprevir (SIM)- or sofosbuvir (SOF)-containing therapy is added to medication profiles of patients with hepatitis C (HCV) monoinfection to ...
Bliss, Steven, Davis, Melissa, Koroglu, Arden, McNutt, Louise-Anne, Miller, Christopher, Nasiri, Mona, Patel, Nimish   +6 more
core   +1 more source

Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents [PDF]

, 2017
Hepatitis C virus (HCV) chronic infection can be associated with extrahepatic manifestations such as mixed cryoglobulinaemia and lymphoproliferative disorders that are endowed with increased rates of morbidity and all-cause mortality.
Burra, Patrizia, Farinati, Fabio, Floreani, Annarosa, Fogar, Paola, Franceschet, Enrica, Gambato, Martina, Nabergoj, Mitja, Pantano, G, Piva, Elisa, Plebani, Mario, Russo, FRANCESCO PAOLO, Schiavinato, Alvise, Tosato, Francesca, Zanetto, Alberto   +13 more
core   +1 more source

Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study

Health Science Reports, 2020
Background and aims Direct‐acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection have resulted in high rates of sustained virologic response (SVR) following 8 to 24 weeks of treatment.
Eric Lawitz, Fred Poordad, Julio A. Gutierrez, Maria Beumont, Greet Beets, Ann Vandevoorde, Pieter Van Remoortere, Donghan Luo, Leen Vijgen, Veerle Van Eygen, Mohamed Gamil   +10 more
doaj   +1 more source

Minimum target prices for production of direct acting antivirals and associated diagnostics to combat Hepatitis C Virus [PDF]

, 2014
Combinations of direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naïve patients. Mass treatment programs to cure HCV in developing countries are only feasible if the costs of treatment and laboratory ...
Cooke, GS, Ford, N, Fortunak, J, Hill, A, Khoo, S, Simmons, B, van der Ven, N   +6 more
core   +2 more sources

Modular Synthesis of Pyritide‐Inspired Macrocycles Featuring Bipyridine Motifs

Angewandte Chemie, Volume 137, Issue 51, December 15, 2025.
A pyritide‐inspired build/couple/pair strategy yields a diverse macrocycle library. This approach expands chemical space and enables the discovery of 6paW, a potent anti‐ferroptotic agent. Abstract Macrocycles represent a promising class of drug‐like scaffolds with unique structural features and the ability to engage challenging targets such as protein–
Ji Hyae Lee, Sihyeong Yi, Juhyun Bang, Hyun Choi, Seung Bum Park   +4 more
wiley   +2 more sources

Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus

Gut and Liver, 2017
Background/AimsThe present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such as elderly and/or cirrhotic ...
Hideyuki Tamai, Yoshiyuki Ida, Akira Kawashima, Naoki Shingaki, Ryo Shimizu, Kosaku Moribata, Tetsushi Nasu, Takao Maekita, Mikitaka Iguchi, Jun Kato, Taisei Nakao, Masayuki Kitano   +11 more
doaj   +1 more source

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response.

PLoS ONE, 2017
BackgroundHCV GT4 accounts for up to 20% of HCV infections worldwide. Simeprevir, given for 12 weeks as part of a 24- or 48-week combination regimen with PR is approved for the treatment of chronic HCV GT4 infection.
Tarik Asselah, Christophe Moreno, Christoph Sarrazin, Michael Gschwantler, Graham R Foster, Antonio Craxí, Peter Buggisch, Faisal Sanai, Ceyhun Bicer, Oliver Lenz, Gino Van Dooren, Catherine Nalpas, Isabelle Lonjon-Domanec, Michael Schlag, Maria Buti   +14 more
doaj   +1 more source

Liver transplantation for viral hepatitis in 2015 [PDF]

, 2016
Liver transplantation (LT) is a life-saving treatment for patients with end-stage liver disease and for patients with liver cell cancer related to liver disease.
Bortoluzzi, Ilaria, Burra, Patrizia, Ferrarese, Alberto, Gambato, Martina, Germani, Giacomo, Nadal, Elena, Russo, FRANCESCO PAOLO, Senzolo, Marco, Zanetto, Alberto   +8 more
core   +1 more source